Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
UK genomics company OutSee has landed an Innovate UK grant to build an agentic AI sub-system that automates the initial triage of drug targets flagged by its core platform, Nomaly. The £50,000 grant — matched by investor Empirical Ventures — aims to remove a key bottleneck in the target validation pipeline. The move could accelerate the discovery of novel therapeutics for conditions like ALS, rare diseases, and metabolic disorders.
UK-based genomics and drug discovery company OutSee has secured funding through Innovate UK's Investor Partnership Grant to develop an agentic AI sub-system that automates early-stage drug target validation. The £50,000 grant, matched by investor Empirical Ventures, will support a pilot study for a prototype system designed to triage outputs from Nomaly — OutSee's AI-driven predictive genomics engine.
Currently, target validation is handled manually by OutSee's scientific team, creating a throughput bottleneck. The new agentic AI layer would handle the initial assessment of Nomaly's high-volume outputs, freeing up researchers to focus on deeper validation work where their expertise matters most. OutSee's in-house pipeline targets neurology, rare, and metabolic diseases, including an ALS-focused project funded by the Longitude Prize.
Key Takeaways:
Why it matters: Bottlenecks in drug target validation slow the entire therapeutic development pipeline. By automating early triage with AI, OutSee could meaningfully compress timelines for bringing novel treatments — particularly for underserved diseases like ALS — closer to patients.
